PREVENTION OF RHEUMATIC FEVER - PowerPoint PPT Presentation

1 / 13
About This Presentation
Title:

PREVENTION OF RHEUMATIC FEVER

Description:

PREVENTION OF RHEUMATIC FEVER Dr. Animesh Mishra, DM (Delhi University) Associate Professor Department of Cardiology NEIGRIHMS Shillong-12 What is Acute Rheumatic fever ? – PowerPoint PPT presentation

Number of Views:175
Avg rating:3.0/5.0
Slides: 14
Provided by: A04
Category:

less

Transcript and Presenter's Notes

Title: PREVENTION OF RHEUMATIC FEVER


1
PREVENTION OF RHEUMATIC FEVER
  • Dr. Animesh Mishra, DM (Delhi University)
  • Associate Professor
  • Department of Cardiology
  • NEIGRIHMS
  • Shillong-12

2
What is Acute Rheumatic fever ?
  • Infectious
  • Immunological
  • Genetic
  • Collagen Vascular Disease
  • Or an unidentified factor.

?
3
Is It Possible to Prevent Rheumatic Fever ?
  • Primordial Prevention
  • Primary Prevention
  • Secondary Prevention

4
Primordial prevention
  • Preventing the development of risk factors
  • Measures for Primordial Prevention
  • 1- Improvement in Socio-Economic Status
  • 2- Prevention of overcrowding
  • 3- Availability of Prompt Medical care
  • 4- Public Education

5
Primary Prevention
  • Measures for Primary Prevention
  • Identification (GAS)
  • Eradication (Penicillin)
  • Susceptible individuals ?
  • Anti Streptococcal Vaccine
  • Theoretical possibility at the community
  • but Possible at individual level

6
Community level prevention Sledge Hammer
Approach
  • 3-20 of sore throat are GAS
  • .3 of GAS sore
    throat result in RF
  • 90 of Patients of RF
    develops RHD
  • 10000 Sore
    throats

10000
3-20 GAS
2000
300
.3 RF
1
6
.
90RHD
5
1
7
Identification and Eradication of GAS -Not
Feasible at community level
  • 1- Asymptomatic sore throat
  • 2- Diagnosis at mass level
  • 3- Identification Methods not 100senstive and
  • specific
  • 4- Route of infection
  • 5- Non compliance with the oral Treatment
  • 6- Treatment failure (Penicillin failure)

8
Susceptible individuals
  • HLA-D 1,2,3,4
  • HLA D 8/17 Indian population
  • B cell alloantigen
  • Results can not be utilized at community level

9
Rheumatic Vaccine
  • Strain specific M-Protein
  • Caveats
  • 1-Hundreds of Strains
  • 2- Fast mutation rate
  • 3- Virulent GAS may not
  • produce M-Protein
  • Polyvalent vaccines- Tried, but not
    successful

10
  • Conserved C-Terminus of M-protein
  • C-5a Peptidase
  • Fibro nectin surface binding Protein (sfb-1)
  • Chemaric peptide J8
  • Polysaccharide conjugated with protein

11
  • Health Education (5-16 years)
  • Education by Parents
  • Teachers
  • All India Radio
  • Doordarshan
  • NICs, CICs

12
  • Health Education (5-16 years)
  • Education by Parents
  • Teachers
  • All India Radio
  • Doordarshan
  • NICs, CICs

13
Secondary PreventionSecondary Attack Rate -50
  • Penicillin Prophylaxis Every 2-3 weeks
  • (Depending upon the Age, Wt, Muscle
  • mass )
  • Duration of prophylaxis LIFE LONG
  • 10Yrs/
    Adulthood
  • 5Yrs/
    18Yrs.
  • 1Yrs
  • Anaphylactic Shock 1 1000000 105
  • Secondary Prevention cannot reduce the burden of
    RHD
  • SS
Write a Comment
User Comments (0)
About PowerShow.com